A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT)for Primary Refractory and Relapsed Acute Myelogenous Leukemia
Sponsor: Jazz Pharmaceuticals
Listed as NCT00875693, this PHASE1 trial focuses on Acute Myelogenous Leukemia and Myelodysplastic Syndrome and remains completed. Sponsored by Jazz Pharmaceuticals, it has been updated 10 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Jan 2018 — Feb 2018 [monthly]
Active Not Recruiting PHASE1
Status: Terminated → Active Not Recruiting
-
Sep 2017 — Jan 2018 [monthly]
Terminated PHASE1
-
Mar 2017 — Sep 2017 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
-
Feb 2017 — Mar 2017 [monthly]
Unknown Status PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1
First recorded
Jun 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jazz Pharmaceuticals
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .